Malaria treatment with atovaquone-proguanil in malaria-immune adults: Implications for malaria intervention trials and for pre-exposure prophylaxis of malaria

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 4, 2008, Pages 1493-1495

  Polhemus, Mark E ^a,e   Remich, Shon ^a   Ogutu, Bernhards ^b   Waitumbi, John ^b   Lievens, Marc ^c   Ballou, W Ripley ^c   Heppner Jr , D Gray ^d  

^a U S ARMY   (United States)

^b KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^d WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^e Unit 64109 (MRU)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; ATOVAQUONE PLUS PROGUANIL; MALARIA VACCINE; RABIES VACCINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEMALE; HUMAN; IMMUNITY; IMMUNIZATION; INFECTION PREVENTION; KENYA; MAJOR CLINICAL STUDY; MALARIA; MALE; PATIENT COMPLIANCE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANIMALS; ANTIMALARIALS; ATOVAQUONE; CHEMOPREVENTION; CHLOROGUANIDE; HUMANS; KAPLAN-MEIERS ESTIMATE; KENYA; MALARIA VACCINES; MALARIA, FALCIPARUM; PARASITEMIA; PLASMODIUM FALCIPARUM; TIME FACTORS;

EID: 42049100103     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01367-07     Document Type: Article

References (11)

1. Alonso, P. L., J. Sacarlal, J. J. Aponte, A. Leach, E. Macete, J. Milman, I. Mandomando, B. Spiessens, C. Guinovart, M. Espasa, Q. Bassat, P. Aide, O. Ofori-Anyinam, M. M. Navia, S. Corachan, M. Ceuppens, M. C. Dubois, M. A. Demoite, F. Dubovsky, C. Menedez, N. Tornieporth, W. R. Ballon, and J. Cohen. 2004. Efficacy of the RTS.S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364:1411-1420.
2. Bejon, P., J. Mwacharo, O. Kai, T. Mwangi, P. Milligan, S. Todryk, S. Keating, T. Lang, B. Lowe, C. Gikonyo, C. Molyneux, G. Fegan, S. C. Gilbert, N. Peshu, K. Marsh, and A. V. Hill. 2006. A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS Clin. Trials 1:e29.
3. Bloland, P. B., T. K. Ruebush, J. B. McCormick, J. Ayisi, D. A. Boriga, A. J. Oloo, R. Beach, W. Hawley, A. Lal, B. Nahlen, V. Udhayakumar, and C. C. Campbell. 1999. Longitudinal cohort study of the epidemiology of malaria infections in an area of intense malaria transmission. I. Description of study site, general methodology, and study population. Am. J. Trop. Med. Hyg. 60:635-640.
4. Boggild, A. K., M. E. Parise, L. S. Lewis, and K. C. Kain. 2007. Atovaquone-proguanil: report from the CDC expert meeting on malaria chemoprophylaxis (II). Am. J. Trop. Med. Hyg. 76:208-223.
5. Butcher, G. A., and R. E. Sinden. 2003. Persistence of atovaquone in human sera following treatment: inhibition of Plasmodium falciparum development in vivo and in vitro. Am. J. Trop. Med. Hyg. 68:111-114.
6. Edstein, M. D., B. M. Kotecka, K. L. Anderson, D. J. Pombo, D. E. Kyle, K. H. Rieckmann, and M. F. Good. 2005. Lengthy antimalarial activity of atovaquone in human plasma following atovaquone-proguanil administration. Antimicrob. Agents Chemother. 49:4421-4422.
7. Looareesuwan, S., C. Viravan, H. K. Webster, D. E. Kyle, D. B. Hutchinson, and C. J. Canfield. 1996. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am. J. Trop. Med. Hyg. 54:62-66.
8. Moortby, V. S., E. B. Imoukhuede, P. Milligan, K. Bojang, S. Keating, P. Kaye, M. Pinder, S. C. Gilbert, G. Walraven, B. M. Greenwood, and A. S. Hill. 2004. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med. 1:e33.
9. Rathod, P. K., T. McErlean, and P. C. Lee. 1997. Variations in frequencies of drug resistance in Plasmodium falciparum. Proc. Natl. Acad. Sci. USA 94:9389-9393.
10. Shanks, G. D., B. O. Ragama, and A. J. Oloo. 1999. Time to reappearance of malaria parasites following various drug treatment regimens in a holoendemic area of western Kenya. Trans. R. Soc. Trop. Med. Hyg. 93:304-305.
11. Shanks, G. D., A. J. Magill, D. O. Freedman, J. S. Keystone, D. J. Bradley, and R. Steffen. 2007. Drug-free holidays: pre-travel versus during travel malaria chemoprophylaxis. Am. J. Trop. Med. Hyg. 77:1-2.